Cell line · CVCL_5916
Papers21
1 to 20 of 21
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Targeted antibody-drug conjugates for rhabdomyosarcoma and other FGFR4-expressing cancers. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Seclidemstat (SP-2577) Induces Transcriptomic Reprogramming and Cytotoxicity in Multiple Fusion-Positive Sarcomas. | Cancer Res Commun | 2025 | Its Methods give the RRID and name the line | PubMed | |
| MyoD is essential in rhabdomyosarcoma by promoting survival through differentiation and CYLD. | iScience | 2025 | Its Methods give the RRID and name the line | PubMed | |
| PubMed 40777370 | bioRxiv | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Evaluation of the Role of AXL in Fusion-positive Pediatric Rhabdomyosarcoma Identifies the Small-molecule Inhibitor Bemcentinib (BGB324) as Potent Chemosensitizer. | Mol Cancer Ther | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Surfaceome Profiling of Cell Lines and Patient-Derived Xenografts Confirm FGFR4, NCAM1, CD276, and Highlight AGRL2, JAM3, and L1CAM as Surface Targets for Rhabdomyosarcoma. | Int J Mol Sci | 2023 | Cellosaurus cites it | PubMed | |
| Single-cell profiling of alveolar rhabdomyosarcoma reveals RAS pathway inhibitors as cell-fate hijackers with therapeutic relevance. | Sci Adv | 2023 | Its Methods give the RRID and name the line | PubMed | |
| SCP4-STK35/PDIK1L complex is a dual phospho-catalytic signaling dependency in acute myeloid leukemia. | Cell Rep | 2022 | Its Methods give the RRID and name the line | PubMed | |
| FGF7-FGFR2 autocrine signaling increases growth and chemoresistance of fusion-positive rhabdomyosarcomas. | Mol Oncol | 2022 | Its Methods give the RRID and name the line | PubMed | |
| Selective Modulation of a Pan-Essential Protein as a Therapeutic Strategy in Cancer. | Cancer Discov | 2021 | Its Methods give the RRID and name the line | PubMed | |
| NuRD subunit CHD4 regulates super-enhancer accessibility in rhabdomyosarcoma and represents a general tumor dependency. | Elife | 2020 | Its Methods give the RRID and name the line | PubMed | |
| Measurement of differential chromatin interactions with absolute quantification of architecture (AQuA-HiChIP). | Nat Protoc | 2020 | Its Methods give the RRID and name the line | PubMed | |
| A mass spectrometric-derived cell surface protein atlas. | PLoS One | 2015 | Cellosaurus cites it | PubMed | |
| The PAX3-FOXO1 fusion protein present in rhabdomyosarcoma interferes with normal FOXO activity and the TGF-β pathway. | PLoS One | 2015 | Cellosaurus cites it | PubMed | |
| Proof-of-concept rare cancers in drug development: the case for rhabdomyosarcoma. | Oncogene | 2014 | Cellosaurus cites it | PubMed | |
| Human rhabdomyosarcoma cell lines for rhabdomyosarcoma research: utility and pitfalls. | Front Oncol | 2013 | Cellosaurus cites it | PubMed | |
| Characterization of genetic lesions in rhabdomyosarcoma using a high-density single nucleotide polymorphism array. | Cancer Sci | 2013 | Cellosaurus cites it | PubMed | |
| Genomic imbalances in rhabdomyosarcoma cell lines affect expression of genes frequently altered in primary tumors: an approach to identify candidate genes involved in tumor development. | Genes Chromosomes Cancer | 2009 | Cellosaurus cites it | PubMed | |
| Gene expression profiling of alveolar rhabdomyosarcoma with cDNA microarrays. | Cancer Res | 1998 | Cellosaurus cites it | PubMed | |
| Detection of the t(2;13)(q35;q14) and PAX3-FKHR fusion in alveolar rhabdomyosarcoma by fluorescence in situ hybridization. | Genes Chromosomes Cancer | 1995 | Cellosaurus cites it | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_5916/papers